CO6361907A2 - Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo - Google Patents

Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo

Info

Publication number
CO6361907A2
CO6361907A2 CO11045145A CO11045145A CO6361907A2 CO 6361907 A2 CO6361907 A2 CO 6361907A2 CO 11045145 A CO11045145 A CO 11045145A CO 11045145 A CO11045145 A CO 11045145A CO 6361907 A2 CO6361907 A2 CO 6361907A2
Authority
CO
Colombia
Prior art keywords
vasoactive agent
osmolit
transdermic
farmaco
supply
Prior art date
Application number
CO11045145A
Other languages
English (en)
Inventor
Stephen Carter
Zhen Zhu
John J Masiz
Kanu Maganbhai Patel
Original Assignee
Biochemics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemics Inc filed Critical Biochemics Inc
Publication of CO6361907A2 publication Critical patent/CO6361907A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación y método para el suministro de sustancias bioactivas cuando se a aplican a, o dentro, de la piel u otra región exterior de un mamífero, por ejemplo un paciente, incluye un agente vasoactivo; un osmolito; y un ingrediente activo; La formulación es lo suficientemente higroscópica para crear una condición de hipertonicidad cuando es absorbida por la piel; Cuando la formulación se aplica a la piel, el agente vasoactivo puede administrarse a la dermis para hacer contacto con la vasculatura de un paciente.
CO11045145A 2008-09-22 2011-04-12 Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo CO6361907A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9912908P 2008-09-22 2008-09-22

Publications (1)

Publication Number Publication Date
CO6361907A2 true CO6361907A2 (es) 2012-01-20

Family

ID=41449932

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11045145A CO6361907A2 (es) 2008-09-22 2011-04-12 Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo

Country Status (7)

Country Link
US (3) US9566256B2 (es)
EP (1) EP2207536A1 (es)
BR (1) BRPI0914192A2 (es)
CA (1) CA2702604C (es)
CO (1) CO6361907A2 (es)
MX (1) MX349176B (es)
WO (1) WO2010034019A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566256B2 (en) * 2008-09-22 2017-02-14 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
BRPI0921959A2 (pt) 2008-12-04 2017-05-30 Biochemics Inc métodos e composições para remoção de tatuagem
WO2012046149A1 (en) 2010-04-28 2012-04-12 Kimberly-Clark Worldwide, Inc. Method for increasing permeability of an epithelial barrier
CA2797205C (en) 2010-04-28 2019-04-16 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of sirna
PT2563450T (pt) 2010-04-28 2017-08-28 Kimberly Clark Co Dispositivo para entrega de medicação para a artrite reumatóide
AU2011288209C1 (en) 2010-04-28 2016-03-24 Kimberly-Clark Worldwide, Inc. Injection molded microneedle array and method for forming the microneedle array
US8512770B2 (en) 2010-08-04 2013-08-20 Dominion Resources Unlimited, Llc Skin penetration composition
WO2013061209A1 (en) 2011-10-27 2013-05-02 Kimberly-Clark Worldwide, Inc. Implantable devices for delivery of bioactive agents
KR20220051429A (ko) 2011-10-27 2022-04-26 소렌토 쎄라퓨틱스, 인코포레이티드 고점도 생체활성 제제의 경피 전달 방법
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
WO2013083431A1 (en) 2011-12-06 2013-06-13 Unilever Plc Skin anti-ageing composition
US9587169B2 (en) * 2012-01-12 2017-03-07 Courtney Gene Rogers Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing
EP2968125A1 (en) 2013-03-15 2016-01-20 BioChemics, Inc. Topical formulations and methods for drug delivery
WO2015066699A1 (en) * 2013-11-04 2015-05-07 ROGERS, Courtney, Gene Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing
EP3624770A1 (en) 2017-05-15 2020-03-25 BioChemics, Inc. Transdermally-delivered combination drug therapy for pain
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
IT201800003902A1 (it) * 2018-03-23 2019-09-23 Sebastiano Turrini Unguento a base di ibuprofene racemico transedermico
MX2021002833A (es) * 2018-09-27 2021-05-27 Biophysics Pharma Inc Sistema de suministro de farmaco transdermico.
AU2021224149A1 (en) * 2020-02-20 2022-09-15 John J. Masiz Transmucosal drug delivery system

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4933184A (en) 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4758599A (en) 1986-06-04 1988-07-19 American Cyanamid Company Clear, hydroalcoholic aftershave lotion which moisturizes, conditions, and prevents irritation
US4830856A (en) 1987-01-27 1989-05-16 Peppers James M Chelation product
US4859704A (en) 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
GB8905815D0 (en) 1989-03-14 1989-04-26 Beecham Group Plc Medicament
US5422361A (en) 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US5093133A (en) 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
JP3326174B2 (ja) 1991-05-13 2002-09-17 ザ ブーツ カンパニー ピーエルシー 治療薬
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5451704A (en) 1992-12-23 1995-09-19 Mobil Oil Corporation Alpha-olefin oligomerization using supported metal halide catalysts
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5645854A (en) 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5460821A (en) 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
IT1265001B1 (it) 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5527530A (en) 1994-07-08 1996-06-18 The Procter & Gamble Company Alcoholic moisturizing after shave lotion
US5496827A (en) 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US6228873B1 (en) * 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6527716B1 (en) 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
EP0973384A4 (en) 1997-02-13 2004-10-13 Sky High Llc ORGAN PRESERVATION SOLUTION
US5980882A (en) 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US5922332A (en) 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US5895658A (en) 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US6486206B1 (en) 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
WO1999051157A1 (en) 1998-04-07 1999-10-14 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
AU779783B2 (en) * 1999-05-17 2005-02-10 Eisai Inc. Improved cellular uptake of bioactive agents
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
US7105172B1 (en) 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
FR2808191B1 (fr) 2000-04-28 2004-03-05 Oreal Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
AU2001290552A1 (en) 2000-09-15 2002-03-26 Medical Merchandising, Inc. Pain reliever and method of use
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US6936589B2 (en) * 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
US20030091659A1 (en) 2001-11-09 2003-05-15 Avon Products, Inc. Topical composition having undifferentiated plant seed cells and method for using same
US20030104043A1 (en) 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
JP2005518823A (ja) 2002-03-08 2005-06-30 マクギル・ユニバーシテイ 未成熟ヒト卵母細胞の体外成熟
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
ES2379464T3 (es) 2002-06-17 2012-04-26 Taro Pharmaceuticals U.S.A., Inc. Suspensión de ibuprofeno
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1603476A4 (en) 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
US6927206B2 (en) 2003-06-06 2005-08-09 Procyte Corporation Compositions and methods for treatment of rosacea
US20080112909A1 (en) 2003-06-24 2008-05-15 Ppg Industries Ohio, Inc. Compositions for providing color to animate objects and related methods
US7375139B2 (en) * 2003-08-18 2008-05-20 Aldred Katherine M Transdermal method and apparatus
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
ITMI20032322A1 (it) 2003-11-27 2005-05-28 Carlo Ghisalberti Dispositivo atossico per facilitare la venipuntura.
EP1740047A2 (en) 2004-03-11 2007-01-10 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
WO2005102282A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20050256204A1 (en) 2004-05-11 2005-11-17 Bitter Patrick H Sr Topical phenyl-epinephrine Rosacea treatment
GB0413635D0 (en) 2004-06-18 2004-07-21 Smith & Nephew Ultrasonic treatment
US20060013866A1 (en) 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
US20060062836A1 (en) 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
US20060217690A1 (en) 2005-03-22 2006-09-28 Bastin Norman J Method for treating various dermatological and muscular conditions using electromagnetic radiation
WO2006104660A1 (en) 2005-03-24 2006-10-05 Avery Dennison Corporation Occlusive wound dressing useful in tattoo removal
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
US20070166252A1 (en) 2005-12-30 2007-07-19 Judy Hattendorf Method of treating skin requiring tattoo removal
JPWO2007086395A1 (ja) 2006-01-24 2009-06-18 財団法人浜松科学技術研究振興会 光線力学的療法用キット
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
WO2007103555A2 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US7887848B2 (en) * 2006-05-31 2011-02-15 Interhealth Nutraceuticals, Inc. Nutraceutical treatments for diabetic and non-diabetic wound healing
CN101534862A (zh) 2006-10-12 2009-09-16 乐敦制药株式会社 用于皮肤的外用制剂
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
WO2008109124A1 (en) 2007-03-06 2008-09-12 Novalar Pharmaceuticals, Inc. Use of nitroglycerin to reverse local anesthesia
CA2680823A1 (en) * 2007-03-19 2008-09-25 Sirtris Pharmaceuticals, Inc. Biomarkers of sirtuin activity and methods of use thereof
US8354116B2 (en) 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US20090123570A1 (en) * 2007-11-09 2009-05-14 Warner W Randolph Composition and method for treating sore throat
WO2009094473A1 (en) * 2008-01-22 2009-07-30 Biochemics, Inc. Methods and compositions for topical treatment of medical conditions including wounds and inflammation
WO2009111075A2 (en) 2008-03-07 2009-09-11 Frank Pellegrini Ultra bright led induced tattoo removal
CA2727710C (en) 2008-06-11 2016-11-01 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
AU2009291755B2 (en) 2008-09-10 2016-04-21 Biochemics, Inc. Ibuprofen for topical administration
US9566256B2 (en) 2008-09-22 2017-02-14 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
BRPI0921959A2 (pt) 2008-12-04 2017-05-30 Biochemics Inc métodos e composições para remoção de tatuagem

Also Published As

Publication number Publication date
US20160128957A1 (en) 2016-05-12
US20100076035A1 (en) 2010-03-25
BRPI0914192A2 (pt) 2015-11-03
US9566256B2 (en) 2017-02-14
MX2010004169A (es) 2010-10-05
EP2207536A1 (en) 2010-07-21
CA2702604A1 (en) 2010-03-25
WO2010034019A4 (en) 2010-05-20
CA2702604C (en) 2013-12-03
MX349176B (es) 2017-07-14
WO2010034019A1 (en) 2010-03-25
US10751309B2 (en) 2020-08-25
US20160129116A1 (en) 2016-05-12
US10537536B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
CO6361907A2 (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo
US10080763B2 (en) Topical film delivery system
HRP20181028T1 (hr) Dugodjelujuće formulacije inzulina
US20150132345A1 (en) Nitric oxide-sequestering topical formulations
AR065318A1 (es) Formulaciones liquidas de formacion de pelicula dermal para liberacion de droga a la piel
UY32765A (es) Preparaciones insulinicas de accion lenta
PE19496A1 (es) Formulacion de analogo de insulina humana
WO2010068281A3 (en) Contact lens drug delivery device
AR064268A1 (es) Sistema terapeutico transdermico para administracion del principio activo buprenorfina
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
JP2016539921A5 (es)
AR055552A1 (es) Preparacion topica refrescante para parches y metodos para utilizar la misma
MX2010004388A (es) Formulaciones de hormona paratiroidea y usos de las mismas.
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR056538A1 (es) Formulacion acuosa hfsh
RU2016119746A (ru) Стабильный состав инсулина глулизин
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
CA2946568A1 (en) Peroxide formulations and methods and applicators for using the same
AR037116A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
WO2008114376A1 (ja) メラニン生成抑制組成物
WO2012106058A3 (en) Animal treatments
WO2008051527A3 (en) Sustained release of agents for localized pain management
AR074820A1 (es) Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa
UY31059A1 (es) Formulaciones de aminoacido n-halogenado
US20230210787A1 (en) Topical cannabinoid compositions, delivery systems, and uses for pain relief

Legal Events

Date Code Title Description
FC Application refused